The effectiveness of insulin glargine 300 U/mL among type 2 diabetes patients: Analysis of a real-world data in Israel

Cheli Melzer Cohen*, Tamar Banon, Varda Shalev, Gabriel Chodick

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Aims: Randomized controlled trials have shown that insulin glargine 300 U/mL (Gla-300) has a more stable and prolonged glucose lowering effect among patients with type 2 diabetes (T2DM) compared to insulin glargine 100 U/mL (Gla-100), resulting in a reduced risk of hypoglycaemia while maintaining a similar efficacy of lowering HbA1c. We aimed to investigate if the effectiveness of Gla-300 is reproducible in real-world settings. Material and methods: In this retrospective cohort study, data from a large state-mandated health organization were used to identify adult T2DM patients who were previously on insulin and initiated Gla-300 therapy between 6/ 2016 and 12/2017. Changes in HbA1c levels, body weight and insulin dose were calculated from baseline period and over a follow-up period of 180 days. Documented hypoglycaemia events were also explored. Results: A total of 1797 patients were included in this study with a mean age of 64.2 (SD = ±11.0y), baseline HbA1c was 8.7 ± 1.6% and 42.5% were females. Among all patients with HbA1c measurement during follow-up (n = 1508), HbA1c was significantly reduced by −0.6% (95% CI −0.6,−0.5; P <.001) from baseline, with a significant reduction in body weight (−0.4 kg; P = <.001). Additionally, a significant (P =.04) reduction of 40.5% in patients with hypoglycaemia events was recorded during follow-up period, from 2.1% (n = 37) at the baseline period to 1.2% (n = 22). Conclusions: This real-world study supports evidence from RCTs regarding the effectiveness of Gla-300 among T2DM patients by improving glycaemic control.

Original languageEnglish
Article numbere00124
JournalEndocrinology, Diabetes and Metabolism
Issue number3
StatePublished - 1 Jul 2020


  • basal insulin
  • glargine-300
  • observational study
  • type 2 diabetes mellitus


Dive into the research topics of 'The effectiveness of insulin glargine 300 U/mL among type 2 diabetes patients: Analysis of a real-world data in Israel'. Together they form a unique fingerprint.

Cite this